Please assess the completion status of the following clinical trial:

Trial Title: Study of Relugolix Alone and Relugolix Combined With Hormonal Add-Back Therapy in Healthy Premenopausal Female Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Pre-menopausal female between 18 and 48 years of age.~2. E2, P, LH and FSH concentrations within 0.5x of the lower limits of normal range and 2x of the upper limits of normal upper limits of normal range (ULN)~3. Regular menstrual periods for the 3 months prior to study enrollment~4. Body weight ≥ 45 killograms (kgs) and body mass index (BMI) of 20 to 36~5. Capable of giving written informed consent~Exclusion Criteria:~1. Pregnancy~2. Lactating Females~3. Any contraindication to the treatment with E2 and NETA~4. Use of the following medications in the 3 months prior to screening: injectable hormonal contraceptives, sex hormone medications or danazol~5. Use of the following medications in the 6 months prior to screening: injectable gonadotropin-releasing hormone agonists, hormonal, or non-hormonal intrauterine devices~6. History of sensitivity to any of the study medications of components thereof or history of drug~7. Significant gynecological, endocrine, metabolic or other health conditions~8. History of regular alcohol consumption within 6 months of study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 48 Years
- Healthy Volunteers: t

Study Arms:
- Relugolix (Type: EXPERIMENTAL): Participants received relugolix 40 milligrams (mg) alone for 6 weeks.
- Relugolix + E2/NETA (Type: EXPERIMENTAL): Participants received relugolix 40 mg and E2/NETA at 1 mg/ 0.5 mg for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).